Opportunity
Federal Register #2026-13402
NCI Seeks Partners for Co-Development and Licensing of Therapeutic Vaccines for HTLV1 and Hepatocellular Carcinoma
Buyer
Substance Abuse and Mental Health Services Administration
Posted
July 02, 2026
Identifier
2026-13402
NAICS
541714, 541715
The National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), is seeking research co-development partners and licensees for two innovative therapeutic vaccine technologies. - Government Buyer: - National Cancer Institute (NCI), Department of Health and Human Services (HHS), National Institutes of Health, Technology Transfer Center - OEMs and Vendors: - No specific commercial OEMs or vendors are named; technologies are developed by NCI - Products/Technologies Requested: - Nucleic acid-based vaccine for HTLV1 infection (Part Number: E1262022) - Generates virus-like particles using HTLV1 Env and gag proteins to trigger immune response - Intended for prevention of HTLV1-associated diseases such as adult T-cell leukemia/lymphoma - Preclinical stage - Viral peptide (CE1)-based immunotherapy for hepatocellular carcinoma (HCC) (Part Number: E0232024) - Synthetic CE1 peptide immunotherapy to induce T cell response against HCC - Discovery stage - Unique/Notable Requirements: - NCI is seeking partners for research co-development and/or licensing - Both technologies are in early (preclinical or discovery) development stages - Focus is on oncology, infectious disease, and immunology applications
Description
The Department of Health and Human Services (HHS) provides notice of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine and the laboratories currently certified to meet the standards of the Mandatory Guidelines using Oral Fluid. The notice lists certified laboratories and IITFs that meet minimum standards to conduct drug and specimen validity tests for federal agencies. It includes information on certification status, suspension, revocation, and withdrawal from the HHS National Laboratory Certification Program. The notice is published monthly and available online.